A research team from Nanyang Technological University, Singapore (NTU Singapore) and Tan Tock Seng Hospital (TTSH) have invented a smart handheld medical device that could enable early intervention for patients with congestive heart failure.
The portable innovation, which resembles a stethoscope, is made up of an acoustic sensor connected to a smartphone. It enables early intervention by allowing patients to check for excess fluid in the lungs at home. Fluid accumulation in the lungs, which causes breathlessness, is a common symptom of congestive heart failure.
One in five people worldwide run the risk of developing congestive heart failure, and this prevalence increases with age. As there is no cure for the ailment, patients can only monitor their health closely with lifestyle changes or medication to prevent their heart function from deteriorating irreversibly.
Currently, patients can only check for fluid accumulation in the lungs by going for a clinical examination, which can be considerably subjective, or through imaging modalities and serum biomarker tests, which are costly and take a longer time.
The non-invasive device built by a team led by NTU Associate Professor Ser Wee and TTSH Associate Professor David Foo circumvents these problems with its portability, ease of use and quick results. Currently a prototype, the device is able to detect any excess fluid in the lungs in 10 seconds once placed on the patient’s chest or back.
In a pilot study using lung sounds recorded from TTSH’s congestive heart failure patients, Assoc Prof Ser and his team found the device to have over 92 per cent accuracy in identifying patients with the condition – comparable to existing ‘gold standard’ diagnosis methods such as X-rays and CT scans. The findings were first presented at the 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
Associate Professor Foo, Head of Cardiology at TTSH, said, “Patients can monitor their condition at home and use the device whenever they feel slightly breathless at home. It is potentially a game-changer in the management of ambulatory heart failure patients. It can also provide a rapid and accurate acute diagnosis of heart failure in situations of undifferentiated shortness of breath symptoms.”
Associate Professor Ser from NTU’s School of Electrical and Electronic Engineering added, “Currently, such diagnosis can only be conducted through clinical examination, which cannot be made frequently. Our smart medical device can be used by anyone, anywhere and any number of times, which will enable the possibility of early intervention of congestive heart failure.
“The next wave of MedTech (medical technology) start-ups will see the massive proliferation of smart medical devices that rely on artificial intelligence (AI) and sensing technologies, such as the one we invented, and that will enable personalised self-assessment and screening of cardiopulmonary and other diseases, and revolutionise the way healthcare is managed in future.”
How it works
In congestive heart failure, the diseased or overworked heart ventricle is unable to pump out enough of the blood it receives from the lungs. This causes pressure to build up first in the heart, then in the veins and capillaries in the lungs. The pressure then pushes fluid back through the capillary walls and into the air sacs of the lungs.
As a result, when air passes through these fluid-filled air sacs, crackles can be heard from the lungs. Depending on the intensity, a crackle may sound like salt added to a hot pan, or Velcro being torn apart. Based on this principle, Prof Ser and his team found a unique set of features that can be used to identify characteristics of sounds unique to patients with fluid accumulation in the lungs. They then developed a proprietary AI algorithm capable of identifying and processing these signals to determine if there is fluid accumulation in the lungs.
The smart medical device developed by NTU and TTSH first picks up breathing sounds through a sound sensor. Through a mobile app, the sound signals are then sent to a server located in the cloud. The NTU-developed algorithm stored in the cloud then processes these sound signals, and the results are shown on the mobile app. This whole process takes about 10 seconds to complete.
Following two rounds of tests with samples collected from 86 patients, the team is now running a third round of tests on the device to further validate its sensitivity and specificity.
A major pharmaceutical company, a healthcare MNC and a local healthcare company have approached the team to explore the possibility of collaborations.
The Latest on: Congestive heart failure
via Google News
The Latest on: Congestive heart failure
- Meta-analysis confirms complete failure of hydroxychloroquine/chloroquine as a COVID-19 treatmenton January 17, 2022 at 5:05 pm
Researchers investigate the efficacy of hydroxychloroquine and chloroquine in the treatment of patients hospitalized with COVID-19.
- Revolutionary implant could ease congestive heart failureon January 15, 2022 at 10:22 pm
Restore Medical is testing a revolutionary implantable device hoped to reduce symptoms and repeat hospitalizations in people with CHF.
- Why this modified pig heart transplant is a huge dealon January 15, 2022 at 9:05 am
The news last week that David Bennett, a 57-year-old Maryland man, nearing death, had undergone cardiac transplant surgery with a genetically modified pig heart sent shock waves through the medical ...
- Dear Doctor: What can I do if new heart medications make it harder to control blood sugar?on January 14, 2022 at 6:04 am
I have been prediabetic for around 13 years and had been able to keep it that way though diet and exercise -- no medications for it. But the real issue now is that I have developed congestive heart ...
- Your Good Health: Heart failure can raise blood sugar in people with prediabeteson January 14, 2022 at 4:54 am
SGLT2 inhibitors such as empagliflozin (Jardiance) are commonly used for diabetes, but have also been shown to reduce hospitalizations in people with heart failure ...
- Dr. Ricardo Bellera, Board-Certified Interventional Cardiologist Joins Modern Heart & Vascularon January 12, 2022 at 7:03 am
Modern Heart and Vascular Institute is excited to welcome board-certified interventional cardiologist Ricardo Bellera, MD, to the team. Dr. Bellera uses a patient-focused, individualized approach to ...
- Mayo Clinic Q&A: Those diagnosed with congestive heart failure should make lifestyle, diet changeson January 11, 2022 at 9:32 pm
My doctor told me that I have congestive heart failure and I have to change my lifestyle, including my diet. What kind of diet should I be on? ANSWER: When patients have congestive heart failure, ...
- Acute Heart Failure (AHF) Therapeutics Market updates, demand analysis and expected growth forecast 2022-2027 | Merck & Co., Novartis AGon January 10, 2022 at 11:35 pm
This report provides an in depth look at the Acute Heart Failure AHF Therapeutics Market including supporting technologies key trends market drivers challenges standardization regulatory environment ...
- Innovative approach brings cell-reprogramming therapy for heart failure closer to realityon January 6, 2022 at 11:53 am
Not too long ago, the idea of taking—for instance—a skin cell and transforming it into a muscle cell was unthinkable. About 10 years ago, however, revolutionary research showed that it is indeed ...
via Bing News